Scinai Immunotherapeutics Ltd. Sponsored ADR (SCNI)
(Delayed Data from NSDQ)
$1.60 USD
0.00 (0.00%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.64 +0.04 (2.50%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SCNI 1.60 0.00(0.00%)
Will SCNI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCNI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for SCNI
Scinai Immunotherapeutics' PC111 featured in peer-reviewed publication
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Scinai (SCNI) Highlights Progress with PC111 in Dermatological Treatments
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy ...
Why Celestica Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket